Evans R
J Allergy Clin Immunol. 1982 Feb;69(2):245-52. doi: 10.1016/0091-6749(82)90106-3.
This is a report of a study from the Committee on In Vitro Tests of the American Academy of Allergy, which evaluated variance of the RAST procedure when different allergic sera were tested by 12 Committee member laboratories using the Phadebas RAST kit (Pharmacia Diagnostics, Piscataway, N.J.) and when serial dilutions of a ragweed allergic sera were sent to nine different commercial laboratories in the U.S.A. The Phadebas RAST was found to differentiate high-, medium-, and low-titer allergic sera. The test was not useful in measuring smaller changes (less than 61%) in specific IgE antibody that might result from treatment with immunotherapy. Alternative methods of reporting the data, percent total activity and percent negative control, were not superior to the Phadebas RAST unit. Four of the commercial laboratories surveyed did not differentiate by their own measure of significance medium- from low-titer ragweed allergic sera.
这是美国过敏学会体外试验委员会的一项研究报告。该研究评估了使用Phadebas RAST试剂盒(法玛西亚诊断公司,新泽西州皮斯卡塔韦)时,12个委员会成员实验室对不同过敏血清进行RAST检测程序的差异,以及将豚草过敏血清的系列稀释液送往美国9家不同商业实验室时的情况。结果发现,Phadebas RAST能够区分高、中、低滴度的过敏血清。该检测对于测量免疫疗法治疗可能导致的特异性IgE抗体较小变化(小于61%)并无用处。报告数据的替代方法,即总活性百分比和阴性对照百分比,并不优于Phadebas RAST单位。接受调查的4家商业实验室无法通过自身的显著性测量来区分中滴度和低滴度豚草过敏血清。